Voya Investment Management LLC Sells 2,151 Shares of KalVista Pharmaceuticals, Inc. $KALV

Voya Investment Management LLC lessened its holdings in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 17.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 10,239 shares of the specialty pharmaceutical company’s stock after selling 2,151 shares during the quarter. Voya Investment Management LLC’s holdings in KalVista Pharmaceuticals were worth $118,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in KalVista Pharmaceuticals by 1.9% during the 1st quarter. Vanguard Group Inc. now owns 2,298,598 shares of the specialty pharmaceutical company’s stock valued at $26,526,000 after buying an additional 43,355 shares in the last quarter. Woodline Partners LP grew its holdings in KalVista Pharmaceuticals by 25.5% during the 1st quarter. Woodline Partners LP now owns 1,617,469 shares of the specialty pharmaceutical company’s stock valued at $18,666,000 after buying an additional 329,068 shares in the last quarter. Emerald Advisers LLC grew its holdings in KalVista Pharmaceuticals by 7.4% during the 1st quarter. Emerald Advisers LLC now owns 898,190 shares of the specialty pharmaceutical company’s stock valued at $10,365,000 after buying an additional 62,140 shares in the last quarter. Parkman Healthcare Partners LLC purchased a new position in KalVista Pharmaceuticals during the 1st quarter valued at approximately $8,698,000. Finally, Emerald Mutual Fund Advisers Trust grew its holdings in KalVista Pharmaceuticals by 10.6% during the 1st quarter. Emerald Mutual Fund Advisers Trust now owns 608,213 shares of the specialty pharmaceutical company’s stock valued at $7,019,000 after buying an additional 58,525 shares in the last quarter.

KalVista Pharmaceuticals Stock Down 1.1%

KALV opened at $12.05 on Thursday. The business has a fifty day moving average of $13.48 and a 200 day moving average of $12.90. KalVista Pharmaceuticals, Inc. has a 52-week low of $7.30 and a 52-week high of $17.28. The stock has a market cap of $608.77 million, a P/E ratio of -3.06 and a beta of -0.15.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its quarterly earnings data on Thursday, September 11th. The specialty pharmaceutical company reported ($1.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.21). The company had revenue of $1.43 million during the quarter, compared to the consensus estimate of $1.97 million. Equities analysts anticipate that KalVista Pharmaceuticals, Inc. will post -3.56 EPS for the current fiscal year.

Analysts Set New Price Targets

KALV has been the subject of several research analyst reports. JMP Securities raised their price target on KalVista Pharmaceuticals from $27.00 to $28.00 and gave the company a “market outperform” rating in a report on Friday, September 12th. Needham & Company LLC reiterated a “buy” rating and issued a $28.00 target price on shares of KalVista Pharmaceuticals in a report on Friday, September 12th. Leerink Partners lifted their target price on KalVista Pharmaceuticals from $18.00 to $20.00 and gave the stock an “outperform” rating in a report on Monday, July 7th. Finally, HC Wainwright lifted their target price on KalVista Pharmaceuticals from $20.00 to $27.00 and gave the stock a “buy” rating in a report on Tuesday, July 8th. One investment analyst has rated the stock with a Strong Buy rating and eight have given a Buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $26.43.

Insiders Place Their Bets

In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 32,979 shares of KalVista Pharmaceuticals stock in a transaction on Wednesday, July 9th. The stock was sold at an average price of $15.69, for a total transaction of $517,440.51. Following the completion of the sale, the chief executive officer directly owned 369,595 shares of the company’s stock, valued at $5,798,945.55. The trade was a 8.19% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Paul K. Audhya sold 2,942 shares of KalVista Pharmaceuticals stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $13.22, for a total value of $38,893.24. Following the sale, the insider directly owned 119,841 shares of the company’s stock, valued at approximately $1,584,298.02. This trade represents a 2.40% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 59,835 shares of company stock valued at $892,350. 4.30% of the stock is owned by company insiders.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).